Medincell Stock Rebounds by 2.5% and Moves Above Its Moving Averages
The biotech company from Montpellier moves forward in early afternoon, going against a downward trending Parisian market. The stock ranks among the top gainers in the SBF 120, continuing the rebound that began after the fall following the annual accounts published in mid-June.
Medincell Moves Above Its Three Key Moving Averages
Medincell stock gains 2.5% to €26.63 during the session, up from a last close at €25.98. This marks a weekly gain of 10.6%, partially offsetting a monthly decline of 6.4%. Over a year, the performance is nearly 59%.
Today's movement repositions the stock above its three main moving averages, with a gap of 0.68% over the MM20 (€26.45), 1.91% over the MM50 (€26.13), and 1.87% over the MM200 (€26.14). This reconvergence of the three curves around the price indicates stabilization after the post-publication turbulence. The RSI at 49 remains neutral, with no extreme signals, and the price is now midway between the support at €24.08 and the resistance at €28.52.
Shift Towards Recurring Revenues Sets the Direction After the June 16 Publication
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The session extends the recovery that began on June 18, the day after the penalty imposed following the annual accounts publication. In the 2025/2026 fiscal year (published on June 16), royalties from Uzedy jumped by 42% to €9.3 million, while the net loss widened to €31.3 million due to accelerated R&D investments and the absence of exceptional revenues. The company identified, during the same publication, the commercial launch of olanzapine LAI scheduled for Q4 2026, alongside the continued increase in Uzedy royalties.
The expected rise in operating expenses remains cited among the risks. In the short term, a clear crossing of the €28.52 resistance will be the next technical threshold to watch to validate the exit from the consolidation zone opened in mid-June.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
